CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted…
Gynecological cancer
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted…
Azenosertib may be effective at treating cyclin E1+ PROC: Study
About a third of women with cyclin E1+ platinum-resistant…
